Astrocytes and therapeutics for Parkinson's disease. - Wikidata - awgldk - TriplyDB

Astrocytes and therapeutics for Parkinson's disease.

Astrocytes and therapeutics for Parkinson's disease.

http://www.wikidata.org/entity/Q34168266

about

Human Stem Cell-Derived Astrocytes: Specification and Relevance for Neurological Disorders Mitochondrial dysfunction in Parkinson's disease Potential of Neural Stem Cell-Based Therapy for Parkinson's Disease Deep brain stimulation: are astrocytes a key driver behind the scene?Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling Precursor cell biology and the development of astrocyte transplantation therapies: lessons from spinal cord injury CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.Isothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson's Disease Protective Microglia and Their Regulation in Parkinson's Disease Protection by Neuroglobin Expression in Brain Pathologies Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity.Astrocyte Dysfunction in Developmental Neurometabolic Diseases.Sigma-1 receptor: a potential new target for Parkinson's disease?A guide to neurotoxic animal models of Parkinson's disease Comorbidities in Neurology: Is adenosine the common link?Alteration in Nuclear Factor-KappaB Pathway and Functionality of Estrogen via Receptors Promote Neuroinflammation in Frontal Cortex after 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Treatment 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA.Protection of dopaminergic cells by urate requires its accumulation in astrocytes Neuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation Resveratrol Produces Neurotrophic Effects on Cultured Dopaminergic Neurons through Prompting Astroglial BDNF and GDNF Release.High-Throughput Phenotypic Screening of Human Astrocytes to Identify Compounds That Protect Against Oxidative Stress.TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease.Sex-specific disruption of murine midbrain astrocytic and dopaminergic developmental trajectories following antenatal GC treatment.Potential Role of Caffeine in the Treatment of Parkinson's Disease.Traumatic Brain Injury Leads to Development of Parkinson's Disease Related Pathology in Mice Astrocyte barriers to neurotoxic inflammation.Enduring, Sexually Dimorphic Impact of In Utero Exposure to Elevated Levels of Glucocorticoids on Midbrain Dopaminergic Populations New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's disease Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease.Translational potential of astrocytes in brain disorders.Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.Immune-mediated processes in neurodegeneration: where do we stand?The astrocytic response to the dopaminergic denervation of the striatum.Astrocytes: inexplicable cells in neurodegeneration.PDGF-BB protects mitochondria from rotenone in T98G cells.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

P2860

Q26740032-D808A7FA-0651-4741-ABE1-30CDF2E0D8F0 Q26741872-D31AB259-E3B1-4137-8BCF-B95818EB709D Q26776154-9CF3C1B0-A83E-4B93-BB1B-D0112F99B746 Q26830147-A3AD50FD-1B5C-46C6-964F-DAF845552BEE Q26849232-0F64746D-4B5E-43FD-A776-94BA611A15D5 Q26864995-15BAA14F-C2F2-4E67-815B-C35A030BCCCF Q27004382-3A5ACDF5-721D-47E8-9F21-A6388E7732B6 Q27324500-14D0DBDE-2131-470E-ADAD-18968037AF60 Q28079206-003A5F2D-2134-4B59-AC66-F70C92797638 Q28079731-AD236458-A480-46D2-82F3-495829AFF8AC Q28079997-1ABB676F-ECE7-40C5-B594-C74C0A58E4F4 Q34310129-89B91102-4812-4A22-BEBA-284BECDD59F8 Q34679071-FA6DBACD-BE35-4449-BFF2-81186AD2C119 Q35537759-2BCF81E4-227A-40E4-9519-8F813CEB6605 Q35603488-C6410876-5225-4F86-8FC3-C2E4165AE9D4 Q35956389-A6A8ECCD-3FD5-4659-A1D0-23C6F849805C Q36056363-39916DB5-F682-4720-ADA2-ED78B82B399C Q36085198-A63BB770-1C4F-4165-9B8A-255C59B57EC5 Q36223240-73FE85F3-5150-4B4D-A401-1ABABD48A89D Q36238937-EB66EE1A-BD62-4FA4-B1EB-86B1ECAA9F4B Q36477181-C99CECD9-89D8-4DD6-8041-81A3AC93F4C3 Q36808557-1FF57996-30B7-4B5D-A727-6FB3FFA900D7 Q36824652-7C7281CB-3000-45AE-B26E-FFFBF0C521FB Q36915459-CE8DA711-36BE-448A-A2F0-3C741A4B6310 Q36944927-74F1E613-3373-4FD9-B302-DF0D12547279 Q37129378-B3EFFAB3-17B2-4758-B9FF-9F67E54DDE37 Q37334985-19D3309A-603F-43BC-86B8-4E20B0A099CD Q37597818-3A1AD4D1-3908-4B6F-89BF-F486CB9ADDF9 Q37631176-4DB50F7B-1B22-44B5-A1E5-8CA02600E83A Q38075712-E3E1BA3E-47EB-4389-862B-ECD274DA16B4 Q38103856-5B1CB9BF-C314-4DB0-845A-822D21D3611E Q38241183-C4A3FDD0-0243-43D3-81F7-762790F9B602 Q38589482-99FEAAAA-1FDD-4CDD-ADC9-30B89BB19142 Q38598375-850FAD98-9ACA-48ED-A672-79AF2FD2E3D0 Q38701423-10088E40-ABE3-4C8C-A1ED-FBABA18FFE9C Q38731476-FAA97712-E55A-4A08-8D5F-709D0C3C9D0A Q38768239-BBD8A980-F229-455D-B458-3E67E0D40B9D Q38795492-1DB43FE1-BCE4-4935-86BE-71281DF7D2EA Q38927864-1490A138-8383-4DEF-91F3-9A8996D78F82 Q38951947-225D89B4-65E6-4DB2-B571-5F84325D0DF1

P2860

Astrocytes and therapeutics for Parkinson's disease.

http://www.wikidata.org/entity/Q34168266

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Astrocytes and therapeutics for Parkinson's disease.

@ast

Astrocytes and therapeutics for Parkinson's disease.

@en

Astrocytes and therapeutics for Parkinson's disease.

@nl

type

label

Astrocytes and therapeutics for Parkinson's disease.

@ast

Astrocytes and therapeutics for Parkinson's disease.

@en

Astrocytes and therapeutics for Parkinson's disease.

@nl

prefLabel

Astrocytes and therapeutics for Parkinson's disease.

@ast

Astrocytes and therapeutics for Parkinson's disease.

@en

Astrocytes and therapeutics for Parkinson's disease.

@nl

P1433

Q34168266-31300730-6749-4423-B481-C0924438DE23

P1476

Q34168266-E646A1DD-6CE9-4C6D-8566-C656C56F340C

P2093

Q34168266-554734DB-B2DD-4ECF-B7FE-73CF05AFB30B

Q34168266-6619FE4D-72DB-417B-BE55-82DCE322031B

P2860

Q34168266-00F530D8-12D7-4279-8443-EEB8DB40EDE3

Q34168266-01F00DAC-015E-47BF-A5D1-06E4A4157AC3

Q34168266-026593B5-32DA-4686-BA5B-8017EEAF26AC

Q34168266-05246552-7588-4845-9A0F-021993D066B6

Q34168266-062AB531-BA63-4252-832C-5AC719CACD7B

Q34168266-07E5C62C-0355-465E-B354-1A11D0E45ACB

Q34168266-0D737F20-C8FB-4F1C-A33C-EAF65AC43681

Q34168266-0E63CAA7-63BF-4E59-BC19-63F1766EFE4B

Q34168266-0EC5D0E3-A0F3-485A-AEA0-6A861D75EC53

Q34168266-0FE0F599-FB9E-45B2-A6F4-9F14B0F359BB

P2888

Q34168266-99A2DF37-89F9-4EF8-8CCB-85D872D8AD83

P304

Q34168266-C874FD9D-6FB0-4764-AB59-865C2F59966B

P31

Q34168266-DE0E01D8-3811-4078-8CB1-2A4F4540706E

P356

Q34168266-E23FD29B-716E-445E-B763-BD5D9E04D62E

P433

Q34168266-EA633F1D-855E-4356-87E1-9AF0B890F828

P478

Q34168266-55AC08B5-92FF-49C5-82FE-B2F6D98FA3CB

P577

Q34168266-253F2165-3C0F-4F38-9F05-197ED0F29BFD

P5875

Q34168266-058911B1-049B-4986-9AB2-64079C2570D0

P6179

Q34168266-1FF40D0C-CD2E-4EA3-88C1-F4235F6CD4F7

P698

Q34168266-3E184527-DCF7-4401-8DA8-C045824640B5

P921

Q34168266-2dd53d22-841c-47ea-9a44-16c7f048e1a8

Q34168266-4D294AEB-6691-4895-B00B-6FECEB7CF6BB

P932

Q34168266-9BD41759-5D84-4ACF-9752-F0853A2BD26B

P356

J.NURT.2010.07.001

P1433

Neurotherapeutics

P1476

Astrocytes and therapeutics for Parkinson's disease.

@en

P2093

Kim Tieu

http://www.w3.org/2001/XMLSchema#string

Phillip M Rappold

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease

DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2

Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism

Inhibition of monoamine oxidase B in the brains of smokers

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease

Adenosine signaling and function in glial cells

A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death

The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress

P2888

j.nurt.2010.07.001

P304

413-423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NURT.2010.07.001

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46819816

http://www.w3.org/2001/XMLSchema#string

P6179

1014280403

http://www.w3.org/2001/XMLSchema#string

P698

20880505

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2948546

http://www.w3.org/2001/XMLSchema#string